Healios K.K. (HLOSF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 57.26 means the share price is 57.26 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $243M is the value of all shares combined. Beta 1.40: the stock has moved about 40% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerHealios K.K. (HLOSF) trades at $1.80. Healios K.K. (HLOSF) is a biotechnology firm based in Tokyo, Japan, specializing in cell therapy and regenerative medicine. Market cap: $243M, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for HLOSF: HLOSF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HLOSF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
These figures come from statements filed 12 months ago — the most recent this company has published.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
HLOSF: the 2 scored disciplines are evenly split. Dominant signal: Ken Griffin bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Healios K.K. (HLOSF) Healthcare & Pipeline Overview
Healios K.K. is a biotechnology company dedicated to advancing cell therapy and regenerative medicine, with a diverse pipeline targeting critical health issues, including age-related macular degeneration and ischemic stroke, positioning it as a significant player in the global healthcare landscape.
What Is the Investment Thesis for HLOSF?
The company's lead candidates, HLCR011 and HLCR012, are positioned to address age-related macular degeneration, a market projected to grow significantly due to the aging population. Furthermore, HLCL041 aims to tackle metabolic liver disease, which has seen increasing prevalence. The ongoing collaboration with Hyogo Medical University enhances Healios's research capabilities, particularly in eNK cell-based therapies for cancer, potentially unlocking new revenue streams. However, the company faces substantial risks inherent to the biotechnology sector, including the outcomes of clinical trials and regulatory approvals. Monitoring these factors will be crucial to understanding Healios's future growth trajectory.
Based on FMP financials and quantitative analysis
HLOSF Key Highlights
Market Cap of $243M reflects the company's current valuation in the biotechnology sector.
- Profit Margin of -4235.1% indicates significant operational challenges and costs associated with research and development.
- Gross Margin of -529.7% highlights the company's early-stage investment in product development and commercialization.
- Beta of 1.40 suggests higher volatility compared to the broader market, typical for biotech firms.
- No dividend yield as the company reinvests earnings into R&D for future growth.
Who Are HLOSF's Competitors?
HLOSF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | $63.34 | -0.64% | $129B | 905-pillar |
| AMGN Amgen Inc. | $382.47 | -2.25% | $206B | 815-pillar |
| GILD Gilead Sciences, Inc. | $144.81 | -0.58% | $180B | 635-pillar |
| NAGE Niagen Bioscience Inc | $3.04 | -0.49% | $242M | 665-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.74 | -0.38% | $194M | 785-pillar |
| QTTB Q32 Bio Inc. | $10.93 | +1.96% | $325M | 685-pillar |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | 0.00% | $416M | 689-signal |
| CRMD CorMedix Inc. | $7.96 | -0.06% | $624M | 885-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are HLOSF's Key Strengths?
Innovative pipeline with multiple advanced therapies targeting significant health issues.
- Strong collaborative research agreements enhancing R&D capabilities.
- Established presence in key international markets.
What Are HLOSF's Weaknesses?
High operational costs leading to negative profit and gross margins.
- Limited commercialized products, relying heavily on pipeline success.
- Small workforce may limit operational scalability.
What Could Drive HLOSF Stock Higher?
Progress in clinical trials for HLCR011 and HLCR012, targeting age-related macular degeneration.
- Collaborative research with Hyogo Medical University on eNK cell-based cancer immunotherapies.
- Potential regulatory approvals for HLCL041 targeting metabolic liver disease.
What Are the Key Risks for HLOSF?
Financial-distress signal — its Altman Z-Score of 1.55 sits in the distress zone (elevated bankruptcy risk).
- Rich valuation — a P/E of 57.26 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.
- Outcomes of ongoing clinical trials may not meet expectations.
- Regulatory approvals may face delays or rejections.
- Market competition could impact the success of Healios's therapies.
What Are the Growth Opportunities for HLOSF?
- Growth opportunity 1: Healios's pipeline includes HLCR011 and HLCR012, targeting age-related macular degeneration, a condition affecting millions globally. Healios's innovative approach using iPSC-derived therapies positions it to capture significant market share as it advances through clinical trials.
- Growth opportunity 2: The development of HLCL041 for metabolic liver disease taps into a growing market, with increasing cases of liver-related disorders. The global market for liver disease treatments is expected to exceed $20 billion by 2026. Healios's unique regenerative approach could provide a competitive advantage, especially as traditional therapies often fall short in efficacy.
- Growth opportunity 3: HLCM051, aimed at treating ischemic stroke and acute respiratory distress syndrome, addresses critical healthcare needs with limited current treatment options. The global market for stroke management is projected to grow to $34 billion by 2027, presenting Healios with an opportunity to introduce its innovative therapies.
- Growth opportunity 4: The collaboration with Hyogo Medical University on eNK cell-based cancer immunotherapies could lead to breakthroughs in cancer treatment.
- Growth opportunity 5: Expansion into European and U.S. markets provides Healios with access to larger patient populations and advanced healthcare systems. As the company progresses through clinical trials and regulatory approvals, it could significantly enhance its market presence and revenue potential.
What Opportunities Does HLOSF Have?
- Expanding market for regenerative medicine and cell therapies.
- Potential for partnerships with larger pharmaceutical companies.
- Growing demand for innovative treatments in aging populations.
What Threats Does HLOSF Face?
- High competition in the biotechnology sector from established firms.
- Regulatory hurdles and lengthy approval processes for new therapies.
- Market volatility and investor sentiment affecting funding opportunities.
What Are HLOSF's Competitive Advantages?
- Strong focus on innovative regenerative medicine approaches.
- Unique pipeline of iPSC-derived therapies targeting critical health issues.
- Collaborative partnerships with leading medical institutions enhance research capabilities.
- Established presence in multiple key markets (Japan, Europe, U.S.) provides competitive advantage.
What Does HLOSF Do?
Founded in 2011 as Retina Institute Japan, K.K., Healios K.K. rebranded in 2013 and is headquartered in Tokyo, Japan. The company specializes in the innovation, development, production, and commercialization of cell therapy and regenerative medicine products. With a workforce of 65 employees, Healios operates across Japan, Europe, and the United States, focusing on advanced cellular and tissue-based therapies. Its pipeline includes iPSC-derived regenerative medicines such as HLCR011 and HLCR012, which address age-related macular degeneration, and HLCL041, targeting metabolic liver disease. Additionally, HLCM051 is a regenerative treatment aimed at ischemic stroke and acute respiratory distress syndrome, while HLCN061 is under development for solid tumor indications. Healios also collaborates with Hyogo Medical University to research eNK cell-based cancer immunotherapies for mesothelioma. This strategic focus on innovative therapies positions Healios as a forward-thinking entity in the biotechnology sector, addressing unmet medical needs through cutting-edge research and development.
What Products and Services Does HLOSF Offer?
- Develop and commercialize cell therapy and regenerative medicine products.
- Focus on advanced cellular and tissue-based therapies for various diseases.
- Operate in Japan, Europe, and the United States.
- Maintain a robust pipeline of innovative therapies targeting unmet medical needs.
- Collaborate with academic institutions for research and development.
- Utilize iPSC-derived technologies for regenerative treatments.
How Does HLOSF Make Money?
- Generate revenue through the commercialization of approved therapies.
- Engage in partnerships and collaborations for research and development.
- Leverage intellectual property from innovative therapeutic technologies.
- Seek funding through grants and public offerings to support R&D efforts.
What Industry Does HLOSF Operate In?
The biotechnology industry is characterized by rapid innovation and significant investment in research and development. With a global market expected to reach $2.4 trillion by 2028, driven by advancements in personalized medicine and regenerative therapies, Healios K.K. is well-positioned to capitalize on these trends. The competitive landscape includes major players focusing on cell therapy and regenerative medicine, making Healios's specialized pipeline a critical differentiator in a crowded market.
Who Are HLOSF's Key Customers?
- Healthcare providers seeking advanced treatment options for patients.
- Research institutions and universities for collaborative projects.
- Patients suffering from age-related and metabolic diseases.
- Pharmaceutical companies interested in partnerships for therapy development.
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● No analyst coverage
- ● Reported in JPY, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 47 |
| 2026-08-26 | 47 |
| 2026-08-29 | 47 |
| 2026-09-01 | 47 |
| 2026-09-04 | 47 |
| 2026-09-07 | 47 |
| 2026-09-10 | 47 |
What changed?
The score has stayed at 47.
Over the same 18 days the stock moved +0.0%.
Company Profile
Healios K.K. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Tokyo, JP. The company is led by CEO Tadahisa S. Kagimoto. HLOSF has traded publicly since 2020.
Key Financial Metrics
Return on equity for Healios K.K. stands at 3.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.9%, showing how much profit it generates from its asset base. HLOSF trades at a trailing price-to-earnings ratio of 57.26, above the Healthcare sector average of ~21.50x. Its free cash flow yield is -11.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.37 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.5%, the inverse of the P/E and a quick read on earnings relative to price.
HLOSF Valuation & Market Position
With a $243M market cap, Healios K.K. sits in the micro-cap segment of the market.
Quarterly Financial Performance: Healios K.K.
Revenue for Healios K.K. came in at $45K during Q2 FY2026, a 13.7% contraction versus the preceding quarter. The company recorded net income of $7.7M, with diluted EPS of $0.06. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, HLOSF averaged $0.01 in diluted EPS.
Financial Health
Healios K.K.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.55 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Healios K.K. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 73.0% above estimates on average.
HLOSF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Innovative pipeline with multiple advanced therapies targeting significant health issues.
- Strong collaborative research agreements enhancing R&D capabilities.
- Established presence in key international markets.
- Upcoming: Progress in clinical trials for HLCR011 and HLCR012, targeting age-related macular degeneration.
Bear Case
- High operational costs leading to negative profit and gross margins.
- Limited commercialized products, relying heavily on pipeline success.
- Small workforce may limit operational scalability.
- Potential: Outcomes of ongoing clinical trials may not meet expectations.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · June 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $45,221.548 | $8M | $0.06 |
| Q1 FY2026 | $52,385.914 | -$23M | -$0.18 |
| Q4 FY2025 | $162,823.956 | $13M | $0.12 |
| Q3 FY2025 | $125,408.3 | $4M | $0.03 |
Q2 FY2026 · filed 30 Jun 2026 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Converted to USD from JPY at today's rate
HLOSF Latest News
No recent news available for HLOSF.
HLOSF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for HLOSF.
Price Targets
Wall Street price target analysis for HLOSF.
HLOSF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for HLOSF; grades run from A+ (80-100) to F (below 30).
Leadership: Tadahisa S. Kagimoto
CEO
Tadahisa S. Kagimoto has been at the helm of Healios K.K. since its rebranding in 2013. With a background in biotechnology and extensive experience in the healthcare sector, he has played a pivotal role in steering the company's strategic direction. Kagimoto holds a degree in life sciences and has previously worked in various leadership roles within the industry, focusing on innovative therapeutic developments.
Track Record: Under Kagimoto's leadership, Healios has successfully developed a robust pipeline of regenerative therapies and established key partnerships with academic institutions, enhancing the company's research capabilities and market position.
HLOSF OTC Market Information
The OTC Other tier includes stocks that do not meet the listing requirements for higher tiers like NYSE or NASDAQ. Companies in this tier may have less stringent reporting requirements but can also face lower liquidity and higher volatility.
- OTC Tier: OTC Other
- Lower visibility and less stringent reporting standards compared to major exchanges.
- Potential for higher price volatility due to lower trading volumes.
- Limited access to institutional investors may impact stock liquidity.
- Review Healios's clinical trial results and pipeline status.
- Assess financial health through available reports and disclosures.
- Investigate partnerships and collaborations for research and development.
- Monitor regulatory developments affecting product approvals.
- Evaluate competitive landscape and market positioning.
- Established partnerships with reputable academic institutions.
- Presence in multiple key markets (Japan, Europe, U.S.).
- Strong focus on innovative research and development.
Common Questions About HLOSF (Healthcare)
Is HLOSF a good stock?
Stock Expert AI does not rate HLOSF buy, sell or hold. Healios K.K. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the main risks for HLOSF?
Healios K.K. faces several risks inherent to the biotechnology sector, including the potential for unfavorable outcomes in clinical trials, which could hinder the advancement of its product pipeline.
What are the key factors to evaluate for HLOSF?
Evaluate HLOSF on fundamentals, analyst consensus, and risk factors. P/E: 57.26x vs the S&P 500's ~20-25x. Furthermore, HLCL041 aims to tackle metabolic liver disease, which has seen increasing prevalence. Not financial advice.
How frequently does HLOSF data refresh on this page?
HLOSF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven HLOSF's recent stock price performance?
Healios K.K. (HLOSF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative pipeline with multiple advanced therapies targeting significant health issues. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HLOSF overvalued or undervalued right now?
Healios K.K. (HLOSF) trades at 57.26x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of HLOSF?
Yes, most major brokerages offer fractional shares of Healios K.K. (HLOSF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track HLOSF's earnings and financial reports?
Healios K.K. (HLOSF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for HLOSF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on available information as of June 2026. Financial metrics and company status may change over time.